Guggenheim Capital LLC lessened its stake in shares of Steris PLC (NYSE:STE) by 19.8% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 13,025 shares of the medical equipment provider’s stock after selling 3,213 shares during the quarter. Guggenheim Capital LLC’s holdings in Steris were worth $1,823,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Steris by 2.2% during the 1st quarter. BlackRock Inc. now owns 7,498,694 shares of the medical equipment provider’s stock worth $1,049,591,000 after buying an additional 161,410 shares during the last quarter. WCM Investment Management LLC lifted its stake in shares of Steris by 116.7% during the 1st quarter. WCM Investment Management LLC now owns 5,079,325 shares of the medical equipment provider’s stock worth $710,953,000 after buying an additional 2,735,738 shares during the last quarter. State Street Corp lifted its stake in shares of Steris by 2.3% during the 1st quarter. State Street Corp now owns 3,671,585 shares of the medical equipment provider’s stock worth $513,916,000 after buying an additional 83,765 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Steris by 4.1% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 2,031,164 shares of the medical equipment provider’s stock worth $284,303,000 after buying an additional 80,667 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Steris by 47.6% during the 4th quarter. Geode Capital Management LLC now owns 1,394,232 shares of the medical equipment provider’s stock worth $212,095,000 after buying an additional 449,941 shares during the last quarter. Institutional investors own 88.07% of the company’s stock.

NYSE:STE opened at $154.01 on Friday. Steris PLC has a 52 week low of $105.69 and a 52 week high of $168.98. The firm has a market cap of $13.08 billion, a price-to-earnings ratio of 32.29 and a beta of 0.78. The firm’s 50-day simple moving average is $156.37 and its 200 day simple moving average is $151.24. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 2.40.

Steris (NYSE:STE) last released its quarterly earnings results on Wednesday, May 13th. The medical equipment provider reported $1.64 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.07. Steris had a net margin of 13.45% and a return on equity of 16.34%. The business had revenue of $822.99 million for the quarter, compared to analyst estimates of $788.37 million. During the same period last year, the firm earned $1.53 earnings per share. Sell-side analysts anticipate that Steris PLC will post 5.25 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 26th. Shareholders of record on Friday, June 12th were issued a $0.37 dividend. This represents a $1.48 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend was Thursday, June 11th. Steris’s dividend payout ratio is currently 26.24%.

In other Steris news, Director Mohsen Sohi sold 3,218 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $164.12, for a total value of $528,138.16. Following the transaction, the director now directly owns 25,579 shares of the company’s stock, valued at approximately $4,198,025.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by company insiders.

A number of research firms have recently issued reports on STE. Zacks Investment Research upgraded shares of Steris from a “hold” rating to a “buy” rating and set a $174.00 target price for the company in a research note on Friday, April 24th. Stephens raised their price target on shares of Steris from $145.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Finally, Needham & Company LLC initiated coverage on shares of Steris in a research report on Tuesday, June 9th. They set a “hold” rating on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $172.00.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

See Also: How does a dividend reinvestment plan work?

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris PLC (NYSE:STE).

Institutional Ownership by Quarter for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.